Paul M. BisaroExecutive Chairman
Paul Bisaro is Executive Chairman of Amneal Pharmaceuticals, Inc. Mr. Bisaro was named Executive Chairman following Amneal’s merger with Impax Laboratories, Inc. in May 2018.
Previously, Mr. Bisaro served as President and Chief Executive Officer and a member of the Impax Laboratories Board of Directors since March 2017. He is an accomplished global business leader with more than 25 years of generic and branded pharmaceutical experience, and an exceptional track record of driving company growth through operational execution and corporate transformation.
Prior to joining Impax, Mr. Bisaro served as Executive Chairman of Allergan, plc1 from July 2014 to November 2016, as President and CEO of Actavis, plc1 from October 2012 to July 2014, and as President and CEO of Watson Pharmaceuticals, Inc.1 from September 2007 to October 2012.
He also previously served as President, Chief Operating Officer and a member of the Board of Directors of Barr Pharmaceuticals, Inc., a global specialty pharmaceutical company (Barr), from 1999 to 2007. Between 1992 and 1999, Mr. Bisaro served as General Counsel of Barr, and from 1997 to 1999, served in various additional executive leadership capacities.
Prior to joining Barr, he was associated with the law firm Winston & Strawn and a predecessor firm,
Bishop, Cook, Purcell and Reynolds, from 1989 to 1992. He also served as a Senior Consultant with
Arthur Andersen & Co.
Mr. Bisaro currently serves on the Board of Directors of Zoetis, Inc. and on the Board of Visitors of the Catholic University of America’s Columbus School of Law. He also served as Chairman of the Board of the Generic Pharmaceutical Association (GPhA, now Association of Accessible Medicines [AAM]) in 2010 and 2011.
Mr. Bisaro holds an undergraduate degree in General Studies from the University of Michigan and a Juris Doctor from Catholic University of America in Washington, D.C.
1. Watson Pharmaceuticals, Inc. (founded in 1984) changed its name to Actavis, plc following the merger of the two companies in October 2012. Actavis, plc subsequently changed its name to Allergan, plc following the merger of the two companies in March 2015.
Robert StewartPresident and Chief Executive Officer
Robert Stewart is President and Chief Executive Officer of Amneal Pharmaceuticals, Inc. Mr. Stewart was named President and CEO following Amneal’s merger with Impax Laboratories, Inc. in May 2018.
Previously, Mr. Stewart served as Chief Operating Officer of Allergan plc. He has more than 22 years of experience in global brand and generic pharmaceutical leadership, including expertise in M&A integration, operational excellence, supply chain, R&D, quality and manufacturing management.
Prior to his appointment as Chief Operating Officer of Allergan in May 2016, Mr. Stewart served executive leadership roles of increasing responsibility, including as President, Generics and Global Operations from March 2015 to May 2016; Chief Operating Officer from July 2014 to March 2015; and President, Global Operations, from August 2010 to July 2014. He joined Allergan (then Watson) in November 2009 as Senior Vice President, Global Operations. Before joining Watson, Rob held various senior leadership roles with Abbott Laboratories, Inc. (1995 through 2009) as well as Hoffman La-Roche Inc.
Mr. Stewart currently serves as Vice Chair of the Board of The Association for Accessible Medicines (AAM). He has also served as a Member of the Board of the National Association of Manufacturers (NAM) since September 2016, and a member of the Fairleigh Dickinson University Board of Trustees since June 2017.
Mr. Stewart holds a Bachelor’s degree in Business Management and Finance from Fairleigh Dickinson University.
James E. Bauersmith, M.S., Esq.Senior Vice President, Corporate Development
Jamie leads the Corporate Development, Portfolio and Procurement team’s activities focused on identifying opportunities for Amneal, both internal and external, to expand its capabilities, product portfolio and pipeline in Generics, Specialty and biosimilars. Prior to joining Amneal, Jamie served as SVP, Head of Portfolio and Strategic Marketing for Fresenius Kabi where he managed a team responsible for new product development, on-market products, new technology platforms, regulatory approval, procurement, launch management, and business development. Prior to joining Fresenius Kabi, Jamie served as a Senior Counsel for Teva Pharmaceuticals, where he oversaw several of the company’s Hatch-Waxman cases (branded and generic), including Copaxone. He also worked as a patent attorney in the New York office of Frommer Lawrence & Haug on Hatch-Waxman patent litigations) and handled a variety of patent prosecution, trademark, antitrust and unfair competition law topics. He has significant experience with the FTC, FDA, and go-to-market considerations across injectables and retail product lines. Jamie received his B.S. from the University of Notre Dame, his JD from Pennsylvania State University Dickinson School of law, where he graduated with Honors, and an M.S. of Bioscience and Biotechnology from Drexel University focused on molecular cell biology.
Andrew S. BoyerExecutive Vice President, Commercial Operations
Andy most recently served as President and CEO of North America Generics, Teva Pharmaceuticals, Inc. Prior to joining Teva, Andy was Senior Vice President of Sales and Marketing for the U.S. Generics Division at Allergan plc (formerly, Actavis plc; formerly, Watson Pharmaceuticals, Inc.) since September 2006. He joined then Watson in 1998 as Associate Director of Marketing in Generics. Before joining Watson, Andy served as National Accounts Manager for Lederle/American Cyanamid as well as Marketing Manager for Barr Laboratories. He serves as a Director of the Association for Accessible Medicines. Andy received his Bachelor’s degree in Business Administration and Management from State University of New York at Albany.
Todd P. BranningSenior Vice President, Chief Financial Officer
Todd is responsible for leading Amneal’s global finance strategies, including oversight for Finance and Accounting, Internal Audit, Investor Relations and Corporate Communications, and Information Technology. He brings more than 25 years of experience leading the finance and accounting strategies as well as corporate financial planning and analysis (FP&A) for public companies, primarily in the pharmaceuticals sector. Most recently, he served as Senior Vice President, Chief Financial Officer, for Teva Pharmaceuticals’ multi-billion-dollar Global Generic Medicines division. As CFO of Teva Pharmaceuticals’ Global Generic Medicines division, Mr. Branning led the finance function, served on the leadership team responsible for managing the day-to-day operations of Teva’s largest commercial unit and collaborated closely with Investor Relations, Treasury and Information Technology. Prior to joining Teva in 2016, he served as Vice President, Finance, for Allergan plc. Mr. Branning has also served in financial leadership roles at PricewaterhouseCoopers, PPG Industries, Inc. and Merck & Co., Inc. Mr. Branning holds an MBA degree from Carnegie Mellon University and a BBA from the University of Miami. He is a Certified Public Accountant and has completed a CFO certification program from The Wharton School at the University of Pennsylvania.
David A. BuchenSenior Vice President, Chief Legal Officer and Corporate Secretary
David is responsible for leading Amneal’s global legal, Intellectual Property (IP) and corporate compliance functions, as well as aligning the company’s corporate legal strategies to drive Amneal’s continued growth. He brings more than 25 years of experience in the pharmaceutical industry, with notable expertise driving corporate value creation through world-class legal strategies supporting corporate securities, IP, anti-trust, employment, litigation and Mergers & Acquisitions (M&A). Most recently, David served as a consultant to the pharmaceutical industry, providing counsel to various global and U.S. manufacturing, marketing and distribution companies. Prior to establishing his consultancy, he held several executive leadership roles, including serving as EVP – Commercial, North American Generics and International as well as 12 years as Chief Legal Officer and Corporate Secretary supporting Watson Pharmaceuticals’ growth and transformation from a US-focused $500 million generic pharmaceutical company to a $16 billion global specialty leader rebranded as Actavis, plc. David holds a Bachelor of Arts degree from the University of California at Berkeley and a Juris Doctor degree from the George Washington University Law School. He has been recognized by the National Law Journal as one of the Top 50 General Counsels in the U.S.
Joseph GreerSenior Vice President, Global Quality Management
Joe is responsible for leading quality management globally and has more than 27 years of quality and regulatory experience in positions with G&W Labs, Perrigo, KVD Pharma, Pliva, Barr Laboratories, and Novartis Pharmaceuticals. Joe is an active member of various industry organizations, including the American Chemical Society, Regulatory Affairs Professionals Society and the American Society for Quality. He holds bachelor’s degrees in chemistry and biology from Washington & Jefferson College in Washington, Pennsylvania, and a master’s degree in regulatory affairs and quality assurance at Temple University, School of Pharmacy in Pennsylvania.
Miguel GomezSenior Vice President, Technical Operations
Miguel leads the Americas and Ireland Technical Operations team at Amneal. Miguel brings more than 30 years of global pharmaceutical manufacturing operations, supply chain, procurement, operational excellence and IT leadership experience. Prior to joining Amneal, Miguel served as Vice President, Global Supply Chain and Operations at Adare Pharmaceuticals. He has also previously served as Senior Vice President of Manufacturing for the Americas and Ireland at Allergan as well as roles of increasing responsibility with Actavis PLC, Watson Laboratories, Schering-Plough, and Pfizer (Warner Lambert). Miguel has a Bachelor’s degree in Pharmaceutical Science from the University of Puerto Rico, School of Pharmacy.
Dr. Shankar HariharanExecutive Vice President, Chief Scientific Officer
Dr. Hariharan oversees Research & Development, Regulatory Affairs, and Specialty Pharmaceutical Dosage Development. Dr. Hariharan has over 30 years of experience in successfully leading branded and generic pharmaceutical businesses and has held leadership positions at companies including International Development Research, Forest Labs, and Par Pharmaceuticals. Prior to joining Amneal, Dr. Hariharan founded DermAct, an R&D organization specializing in dermatology. Dr. Hariharan completed his bachelor’s degree in pharmacy at Banaras Hindu University in India and his doctorate in pharmacy at Northeastern University in Boston, Massachusetts.
Sanjay JainPresident • India
Sanjay has oversight for all aspects of Amneal India operations, including managing the overall productivity and quality deliverables. He has extensive experience managing Operations, Validation and Quality, as well as Regulatory audits originating from the USFDA, MHRA, EU, TGA, Anvisa, MCC and Health Canada. Prior to joining Amneal, Sanjay held Quality and Operations positions at Ranbaxy Laboratories, Zydus Cadila, Torrent Pharmaceuticals, Cadila Pharmaceuticals, Intas Pharmaceuticals, Bharat Parenterals and Mesco Pharmaceuticals. He has developed quality systems, implemented various process improvement projects, developed and audited API vendor sites across the globe and successfully faced regulatory audits of various regulatory agencies multiple times. He is a member of the International Society for Pharmaceutical Engineering (ISPE) and Parenteral Drug Association (PDA and an accomplished speaker at various international conferences. He holds an undergraduate degree in Pharmacy and a graduate degree in Quality Management.
Kanwal PanditaManaging Partner • RAKS
Dr. Kanwal Pandita has served with Amneal Pharmaceuticals LLC, USA, since 2008. He founded and established Raks Pharma Pvt Ltd, (an API Division of Amneal LLC, USA) and in 2011 joined as Managing Director. He is an accomplished pharmaceutical executive with extensive experience managing the API function and audits originating from the USFDA, EDQM, WHO, Korean FDA etc. Prior to joining Amneal, Dr. Pandita held senior positions in consultancy, operations, and business development at OSB Pharmaceuticals LLC USA, Morepen Inc. USA, Zydus Pharmaceuticals Inc. (USA), Cadila Healthcare Ltd. India and Ranbaxy Laboratories Ltd. India. Dr. Pandita has more than 33 years of experience in the global pharmaceutical industry, has travelled extensively, and has many patents and publications to his credit. He holds a Master’s degree in Organic Chemistry, M.Phil. and Ph.D. in Medicinal/Synthetic Organic Chemistry from RRL, Jammu (a Division of Council of Scientific and Industrial Research, India).
Nikita ShahSenior Vice President, Chief Human Resources Officer
Nikita oversees human resources for Amneal. Prior to joining Amneal, Nikita led the internal audit and human resources functions for Warner Chilcott, a global specialty pharmaceutical company. She also supported corporate M&A, process improvements and systems efficiencies across the organization. Prior to Warner Chilcott, Nikita held roles of increasing responsibilities at AT&T and Deloitte Consulting. Nikita received her master’s degrees in accounting and auditing from Gujarat University, India. She is a certified public accountant.
Joseph TodiscoSenior Vice President, Specialty Commercial
Joe has leadership responsibility for Specialty and International, as well as continued responsibility for the Amneal-Impax integration process. Joe joined Amneal six years ago as the head of Corporate Development and has been an integral part of the management team that executed the Amneal-Impax business combination, as well as multiple other business development, licensing and M&A transactions. In addition to his role in Corporate Development, Joe held management oversight responsibility for Gemini Laboratories, building the company from inception to a highly profitable specialty pharmaceutical platform. Prior to joining Amneal, Joe spent more than five years leading Ranbaxy’s North American Commercial Strategy and Business Development, and held various leadership roles with Par Pharmaceuticals. Prior to working in the pharmaceutical industry, Joe was an investment banker for Oppenheimer & Co. and also worked in financial services for Marsh & McLennan Companies. Joe holds a bachelor’s degree in Economics from Georgetown University in Washington D.C. and an M.B.A. from Fordham Graduate School of Business in New York.